The Food and Drug Administration (FDA) has approved Relyvrio, a new drug for the treatment of ALS (amyotrophic lateral sclerosis or Lou Gehrig's disease), reversing a previous denial after the agency determined that there was insufficient evidence to prove the drug's effectiveness, according to Forbes.
The initial rejection raised the ire of patient advocacy groups, prompting the panel to reexamine their findings. Relyvrio's sponsor, Amylyx Pharmaceuticals, plans to price the drug at $158,000 for a year's supply.
Rick Good spent ten years in the newspaper business, including with The News & Observer (Raleigh, NC) and The Greenville News (Greenville, SC). He co-wrote, with Melinda Coleman, Rutledge to Riley: Governors of South Carolina, 1776–Present (Published by The Greenville News), and is the author of Mind Games Trivia #1 (Amazon). He has recently spent 15 years creating original trivia content through Sounds Good Mobile Entertainment and continues that with his new company, SGME Software. He edits The Smart Reader’s money, real estate, and business coverage.
